Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

REAL PTX - Randomized Evaluation of the Zilver PTX Stent vs. Paclitaxel-Eluting Balloons for Treatment of Symptomatic Peripheral Artery Disease of the Femoropopliteal Artery

Trial Profile

REAL PTX - Randomized Evaluation of the Zilver PTX Stent vs. Paclitaxel-Eluting Balloons for Treatment of Symptomatic Peripheral Artery Disease of the Femoropopliteal Artery

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 28 May 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Paclitaxel (Primary) ; Aspirin; Clopidogrel; Heparin
  • Indications Peripheral arterial disorders; Peripheral artery restenosis
  • Focus Therapeutic Use
  • Acronyms REAL PTX

Most Recent Events

  • 19 Feb 2019 Primary endpoint has not been met. (target lesion revascularization (TLR) (drug-eluting stents (DES) versus drug-coated balloons (DCB))), according to the results published in the Journal of the American College of Cardiology.
  • 19 Feb 2019 Results published in the Journal of the American College of Cardiology
  • 04 May 2015 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top